Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
20.56 USD | -1.91% | -8.70% | +124.70% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The company is in a robust financial situation considering its net cash and margin position.
- The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.33 for the 2024 fiscal year.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 280.38 times its estimated earnings per share for the ongoing year.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
Ratings chart - Surperformance
Sector: Life & Health Insurance
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+124.70% | 4.87B | - | ||
+7.69% | 9.18B | B- | ||
+1.69% | 6.61B | C+ | ||
+9.22% | 5.69B | C | ||
-4.47% | 2.27B | B+ | ||
-5.11% | 1.22B | C | ||
+77.08% | 714M | - | C | |
-4.43% | 143M | - | - | |
-15.80% | 63.97M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- OSCR Stock
- Ratings Oscar Health, Inc.